Bridging waitlist delays with interim buprenorphine treatment: initial feasibility

摘要: Despite the effectiveness of agonist maintenance for opioid dependence, individuals can remain on waitlists months, during which they are at significant risk morbidity and mortality. Interim dosing, consisting daily medication without counseling, reduce these risks. In this pilot study, we examined initial feasibility a novel technology-assisted interim buprenorphine treatment waitlisted opioid-dependent adults. Following induction Week 1, participants (n=10) visited clinic Weeks 2, 4, 6, 8, 10 12 to ingest their under staff observation, provide urine specimen receive remaining doses via computerized Med-O-Wheel Secure device. They also received monitoring an Interactive Voice Response (IVR) platform, as well random call-backs urinalysis adherence checks. The primary outcome was percent negative illicit opioids each 2-week visit, with secondary outcomes past-month drug use, acceptability. Participants achieved high levels abstinence, 90% abstinent 2 4 visits 60% 12. Significant reductions were observed in self-reported use (p<.001), withdrawal craving (p<.001) ASI Drug composite score (p=.008). Finally, administration (99%), IVR calls (97%) (82%) high. shows promise reducing patient societal risks delays conventional treatment. A larger-scale, randomized clinical trial is underway more rigorously examine efficacy approach.